Oncolytics Biotech Advances REO 033 Trial with Promising Pelareorep Data in Hard-to-Treat Colorectal Cancer
New sites opening, patients enrolling, and FDA Type D meeting planned for August 2026.
/ 2 items
New sites opening, patients enrolling, and FDA Type D meeting planned for August 2026.
Oncolytics Biotech receives FDA Fast Track designation for pelareorep in treating KRAS-mutant colorectal cancer, showing promising survival improvements.